Search is Powered by Google
Parkinson's Disease News

CABASER(R) (Cabergoline) Product Information Update

Main Category: Parkinson's Disease
Article Date: 11 Sep 2008 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:3 stars

3 (2 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

Pfizer Australia is due to release new safety updates to the Cabaser® (cabergoline) Product Information which will come into effect on November 1, 2008.

Ongoing review of clinical studies suggests that fibrosis and valvulopathy are associated with ergot-derived dopamine agonists, including Cabaser (cabergoline) and could be linked to cumulative doses of the medicine.

Product Physician, Dr Louise Canny explained that as a result of these studies Pfizer Australia has decided to reduce the maximum daily dose of Cabaser (cabergoline) from 6mg per day to 3 mg per day. "It is anticipated that the reduction in the recommended maximum daily dose of Cabaser along with the current recommendations for assessment of patients prior to commencing therapy and during maintenance therapy included in the Cabaser Product Information, should help reduce the risk of fibrotic reactions," explained Dr Canny.

These changes do not affect the availability of Cabaser 1mg and 2mg tablets which will continue to be available through the Pharmaceutical Benefits Scheme (PBS) but the 4mg tablet will be deleted from the available dosage presentations and existing stock will no longer be PBS reimbursed as of November 1 2008.

Healthcare professionals and Parkinson's Australia have been sent a letter outlining the new update to the Product Information.

Cabaser remains an important treatment option for patients with Parkinson's disease and Pfizer Australia is committed to patient safety.

PBS Information: Restricted Benefit - Parkinson's Disease.

About Pfizer Australia

Pfizer Australia is the nation's leading research-based health care company, investing over $A50m in local research and development annually. It develops, manufactures and markets innovative medicines for both humans and animals.

Pfizer Australia




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
U.S. FDA Approves Requip® XL™, The First And Only Oral Once-daily Non-ergot Dopamine Agonist For Parkinson's Disease
15 Jun 2008
GlaxoSmithKline announced the approval of Requip® XL™(ropinirole extended-release tablets) in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease...


Parkinson's Disease Caregiver image Parkinson's Disease Caregiver

People living with Parkinson's disease face many hurdles, but they don't do it alone. Listen to how one couple is coping with the ups and downs of everyday life with Parkinson's disease...

Living with Parkinson's image Living with Parkinson's

Medications for Parkinson's disease work very well. But symptoms can creep back when they wear off. Discover how one patient is trying to keep life as normal as possible...

View more videos...